Induction therapy with rituximab for lupus nephritis due to prolidase deficiency

Rheumatology (Oxford). 2020 Oct 1;59(10):e57-e59. doi: 10.1093/rheumatology/keaa051.

Authors

Satoshi Sato¹, Takuma Ohnishi¹, Yoji Uejima¹, Mihoko Furuichi¹, Shuichiro Fujinaga², Kohsuke Imai³, Kimitoshi Nakamura⁴, Yutaka Kawano¹, Eisuke Suganuma¹

Affiliations

¹ Division of Infectious Diseases and Immunology.
² Division of Nephrology, Saitama Children's Medical Center, Saitama.
³ Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo.
⁴ Department of Pediatrics, Kumamoto University, Kumamoto, Japan.

PMID: 32107546
DOI: 10.1093/rheumatology/keaa051

No abstract available

Publication types

Case Reports

MeSH terms

Administration, Intravenous
Administration, Oral
Adolescent
Antibiotics, Antineoplastic / administration & dosage
Antibiotics, Antineoplastic / therapeutic use
Drug Therapy, Combination
Female
Glucocorticoids / administration & dosage
Glucocorticoids / therapeutic use
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use*
Induction Chemotherapy / methods*
Lupus Nephritis / blood
Lupus Nephritis / drug therapy*
Lupus Nephritis / etiology
Lupus Nephritis / pathology
Male
Methylprednisolone / administration & dosage
Methylprednisolone / therapeutic use
Mycophenolic Acid / administration & dosage
Mycophenolic Acid / therapeutic use
Prednisolone / administration & dosage
Prednisolone / therapeutic use
Prolidase Deficiency / complications*
Prolidase Deficiency / genetics
Rituximab / administration & dosage
Rituximab / therapeutic use*
Skin Ulcer / drug therapy
Skin Ulcer / etiology
Treatment Outcome

Substances

Antibiotics, Antineoplastic
Glucocorticoids
Immunologic Factors
Rituximab
Prednisolone
Mycophenolic Acid
Methylprednisolone